TD Asset Management Inc lowered its position in Teleflex Incorporated (NYSE:TFX – Free Report) by 2.0% in the second quarter, HoldingsChannel.com reports. The fund owned 470,044 shares of the medical technology company’s stock after selling 9,416 shares during the quarter. TD Asset Management Inc’s holdings in Teleflex were worth $113,765,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of TFX. Exchange Traded Concepts LLC acquired a new position in Teleflex during the 2nd quarter worth $26,000. Cullen Frost Bankers Inc. acquired a new position in Teleflex during the 1st quarter worth $41,000. First Horizon Advisors Inc. lifted its holdings in Teleflex by 39.1% during the 1st quarter. First Horizon Advisors Inc. now owns 178 shares of the medical technology company’s stock worth $45,000 after buying an additional 50 shares in the last quarter. Optiver Holding B.V. acquired a new position in Teleflex during the 1st quarter worth $64,000. Finally, Desjardins Global Asset Management Inc. lifted its holdings in Teleflex by 93.6% during the 1st quarter. Desjardins Global Asset Management Inc. now owns 273 shares of the medical technology company’s stock worth $69,000 after buying an additional 132 shares in the last quarter. Institutional investors own 97.15% of the company’s stock.
Teleflex Stock Performance
TFX stock opened at $203.86 on Tuesday. The business’s fifty day moving average is $198.71 and its 200-day moving average is $225.47. The company has a quick ratio of 2.51, a current ratio of 3.58 and a debt-to-equity ratio of 0.45. The company has a market cap of $9.58 billion, a P/E ratio of 23.90, a price-to-earnings-growth ratio of 2.14 and a beta of 1.04. Teleflex Incorporated has a twelve month low of $177.63 and a twelve month high of $276.43.
Teleflex Dividend Announcement
Analyst Upgrades and Downgrades
Several research firms have issued reports on TFX. Royal Bank of Canada upped their price objective on Teleflex from $218.00 to $228.00 and gave the stock an “outperform” rating in a report on Friday, November 3rd. Morgan Stanley reaffirmed an “equal weight” rating and set a $261.00 price objective on shares of Teleflex in a report on Wednesday, July 19th. Truist Financial upped their price objective on Teleflex from $210.00 to $221.00 and gave the stock a “hold” rating in a report on Monday, November 6th. Piper Sandler upped their price objective on Teleflex from $210.00 to $225.00 and gave the stock a “neutral” rating in a report on Monday, November 6th. Finally, Raymond James cut their price target on Teleflex from $272.00 to $255.00 and set an “outperform” rating on the stock in a research note on Monday, August 7th. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $258.40.
Teleflex Company Profile
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.
- Five stocks we like better than Teleflex
- How to Invest in Lithium and Lithium Stocks
- Utilities may be the best play for a turbulent holiday quarter
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Capitalizing on value: 3 undervalued stocks ready for resurgence
- Investing in the High PE Growth Stocks
- Have investors struck gold with Newmont’s 4.7% yield?
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.